Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01369953 · ClinicalTrials.gov registry record

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

A clinical trial of Coronary Artery Disease and Proteus Syndrome, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
30
Enrollment target
1
Study location

NCT01369953 is a study of Coronary Artery Disease and Proteus Syndrome that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 30 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01369953, a study of Coronary Artery Disease and Proteus Syndrome, has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring large cohorts of diverse populations. Key policy, ethical and legal implications of these developments will need to be understood in order to promote the efficacy and effectiveness of genomic research going forward. An overall aim of this project is to obtain feedback on the informed consent process from some of the earliest particpants in studies using whole genome sequencing. A more specific goal is to characterize the salient personal and public references accessed by participants around the time of the informed consent process. By highlighting trends in participants views about study participation around the time of the initial informed consent process, we aim to advance the development of an ethically and socially relevant vocabulary with which to negotiate future terms of use for personal sequence data in genomic research. Participants will be asked to complete a one-time, semi-structured telephone interview lasting approximately 45 minutes in the period 2-8 weeks following their initial informed consent session at the NIH. They will be recruited from two NIH protocols employing whole genome sequencing for distinct purposes. They The ClinSeqTM Study is a large-scale medical sequencing project investigating the causal role of genetics in cardiovascular disease enrolling both symptomatic and healthy individuals. The Whole Genome Medical Sequencing for Gene Discovery Study (WGMS) enrolls children and adults for full sequencing with the aim of discovering the genetic etiology of rare conditions.

Study Locations (1)

Maryland

  • National Human Genome Research Institute (NHGRI), 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-05-29
Est. Completion 2014-01-31

What the Registry Record Tells You About NCT01369953

The ClinicalTrials.gov registry entry for NCT01369953 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01369953 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01369953 about?

NCT01369953 is a clinical study titled "Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants". Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomedical science will draw increasingly on whole genome sequencing research requiring la...

What is the current status of trial NCT01369953?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2011-05-29. Estimated completion is 2014-01-31.

What conditions does trial NCT01369953 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Proteus Syndrome, Coffin - Sins Syndrome, Familial Isolated Hyperparathyroidism, Dubouitz Syndrome.

Who is sponsoring clinical trial NCT01369953?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01369953 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.